New scan could sharpen detection of childhood cancer

NCT ID NCT04559217

Recruiting now Diagnosis Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of PET/CT scan using a radioactive tracer called 68Ga-DOTATATE to see if it can detect neuroblastoma tumors better than the current standard scan (123I-MIBG). The study will enroll 20 children and young adults with suspected or confirmed neuroblastoma. Researchers will compare the two imaging methods to see if the new scan finds more tumors or different ones, which could change treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-DOTATATE (a radioactive tracer for PET/CT scans)
What this could lead to: If successful, this could provide a more accurate way to image neuroblastoma, helping doctors choose the best treatment for each child.
What could go wrong: This is a small, early-phase study with only 20 participants, so results may not apply to all patients. The new scan may not prove better than the current standard.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA

Contacts and locations

Locations

CHU Ste-Justine
RECRUITING

Montreal, Quebec, J1H 5N4, Canada
CIUSSS de l'Estrie-CHUS Hospital
RECRUITING

Sherbrooke, Quebec, J1H 5N4, Canada
McGill University Health Center - Children's hospital
WITHDRAWN

Montreal, Quebec, H4A 3J1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.